Theravance Biopharma, Inc. (TBPH)
NGM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 26.2M | 20.0M | 45.9M | 17.7M |
| Operating Income | -2.7M | -6.5M | 20.0M | -5.8M |
| Net Income | 54.8M | 3.6M | 61.0M | -4.9M |
| Diluted EPS | $1.08 | $0.07 | $1.15 | $-0.10 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 51.3M | 57.4M | 64.4M | 107.5M |
| Operating Income | -79.1M | -53.3M | -42.4M | -3.6M |
| Net Income | 872.1M | -55.2M | -56.4M | 105.9M |
| Diluted EPS | $11.85 | $-1.00 | $-1.15 | $2.06 |